Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Hypertension / Drug Therapy"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"610 - Medicine & health"
Showing
1
-
10
of
10
Search:
'"Hypertension / Drug Therapy"'
,
query time: 0.39s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
CADTH Canadian Drug Expert Committee recommendation: Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.) : indication : for the reduction of intraocular pressure (IOP) in...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
2
Clinical review report: Latanoprostene bunod (Vyzulta) : (Bausch Health Canada Inc.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
3
Clinical review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
4
Prostaglandin analogues for ophthalmic use : a review of the comparative clinical effectiveness and cost-effectiveness
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
5
Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta) : (Bausch Health Canada Inc.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
6
Prostaglandin analogues for ophthalmic use : a review of comparative clinical effectiveness, cost-effectiveness, and guidelines
by
Islam, Saadul
,
Spry, Carolyn
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
7
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
8
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
9
Clinical review report: Preservative-free latanoprost 50 [m]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Ocular
Hypertension
/
drug
therapy
...
”
Read Now
10
Angiotensin-converting enzyme (ACE) inhibitors : a review of the comparative clinical and cost-effectiveness
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Hypertension
/
drug
therapy
...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 610 - Medicine & health
Year of Publication
From:
To:
Classification
610 - Medicine & health
330 - Economics
2
Language
English
10
Collection
National Center for Biotechnology Information
10
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
3
Islam, Saadul
1
Spry, Carolyn
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22610+-+Medicine+%26+health%22&lookfor=%22Hypertension+%2F+Drug+Therapy%22&type=Subject
Send by Email
×
Loading...